Aclaris Therapeutics (NASDAQ:ACRS) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Aclaris Therapeutics (ACRS) operate in?

Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Aclaris Therapeutics Stock (NASDAQ: ACRS) stock price, news, charts, stock research, profile.

Open	$2.54
Close	$2.57
Volume / Avg.	506.94K / 2.56M
Day Range	$2.46 - $2.59
52 Wk Range	0.95 - 5.17
Market Cap	$272.90M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	42
Short Interest	3.73%
Days to Cover	3.59

Recent News

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.

Anusuya Lahiri

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

Avi Kapoor

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Jul 24

Aug 24

Sep 24

Nov 24

Dec 24

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$2.54
Close	$2.57
Volume / Avg.	506.94K / 2.56M
Day Range	$2.46 - $2.59
52 Wk Range	0.95 - 5.17
Market Cap	$272.90M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	42
Short Interest	3.73%
Days to Cover	3.59

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Aclaris Therapeutics (ACRS) stock?

You can purchase shares of Aclaris Therapeutics (NASDAQ:ACRS) through any online brokerage.

View our list of the best stock brokerages

Who are Aclaris Therapeutics (ACRS) competitors?

Other companies in Aclaris Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Zevra Therapeutics (NASDAQ:ZVRA), Theravance Biopharma (NASDAQ:TBPH), Third Harmonic Bio (NASDAQ:THRD) and Bioage Labs (NASDAQ:BIOA).

What is the forecast, or price target, for Aclaris Therapeutics (ACRS) stock?

Aclaris Therapeutics has a consensus price target of $12.38.

What is the current price for Aclaris Therapeutics (ACRS)?

The stock price for Aclaris Therapeutics (NASDAQ: ACRS) is $2.55 last updated January 17, 2025 at 7:49 PM EST.

Does Aclaris Therapeutics (ACRS) pay a dividend?

There are no upcoming dividends for Aclaris Therapeutics.

When is Aclaris Therapeutics (NASDAQ:ACRS) reporting earnings?

Aclaris Therapeutics’s Q4 earnings are confirmed for Tuesday, February 25, 2025.

Is Aclaris Therapeutics (ACRS) going to split?

There is no upcoming split for Aclaris Therapeutics.

What sector and industry does Aclaris Therapeutics (ACRS) operate in?

Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Aclaris Therapeutics

Aclaris Therapeutics (ACRS) Forecast